About usASPENBeiGeneEHAESMONSCLCPD-1Waldenström

Non-inferiority study comparing Zanubrutinib vs. Bendamustine

 Back  View
Non-inferiority study comparing Zanubrutinib vs. Bendamustine
 SLIDE KIT   1   06/2020
 View

Non-inferiority study comparing Zanubrutinib + Rituximab vs. Bendamustine + Rituximab as 1L treatment in MCL

Rating

Rate this resource

Related resources

Pivotal phase 3 study of Zanubrutinib vs. Bendamustine
Pivotal phase 3 study of Zanubrutinib vs. Bendamustine
Zanubrutinib - Mode of Action
Zanubrutinib - Mode of Action
Trial in progress: a phase 3, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma (MCL)
Trial in progress: a phase 3, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma (MCL)
 Back